Perspective Therapeutics (CATX) Deferred Taxes (2023 - 2024)
Perspective Therapeutics recorded quarterly Deferred Taxes of -$2.1 million in Q4 2024, down 126.72% quarter-over-quarter from $7.8 million in Q4 2023, and down 126.72% year-over-year from $7.8 million in Q1 2024.
Perspective Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at -$2.1 million for Q4 2024.
- In Q4 2024, Deferred Taxes fell 126.72% year-over-year to -$2.1 million; the TTM figure through Dec 2024 stood at -$2.1 million (up 20.9% YoY), while the FY2025 annual figure was -$793000.0, up 62.18% from the prior year.
- Deferred Taxes came in at -$2.1 million for Q4 2024 at Perspective Therapeutics, down from $7.8 million in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $7.8 million in Q4 2023 to a low of -$10.5 million in Q1 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -33.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -101.00 Mn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -351.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -9.40 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 300,000.00 |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -16.70 Mn |
| 10 | Perspective Therapeutics | 380.23 Mn | 380.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.10 Mn |
| Dec 31, 2023 | 7.85 Mn |
| Mar 31, 2023 | -10.50 Mn |